跳至主要内容
临床试验/NL-OMON54826
NL-OMON54826已完成4 期

Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. - VITA

RIVM0 个研究点目标入组 385 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
385

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Be 25 years or older at the time of inclusion.
  • Have received a seasonal influenza vaccination in previous season (2018-2019).
  • Be capacitated.
  • Have signed Informed Consent

排除标准

  • Having had a previous pneumococcal vaccination (PCV or the 23-valent
  • pneumococcal polysaccharide vaccine (PPV23)).
  • Known or suspected allergy to any of the vaccine components or having
  • experienced a previous severe adverse reaction to any vaccine.
  • Receipt of any high-dose (>= 20 mg of prednisone daily or equivalent) daily
  • corticosteroids (local incl. inhaled steroids are acceptable) within 2 weeks of
  • study entry
  • Repeated use of any high dose of corticosteroids (a dose of > 30 mg of
  • prednisone or equivalent per day for multiple days) in the recent past.
  • Receipt of an organ- or bone marrow transplant
  • Have a (functional) asplenie.
  • Receipt of chemotherapy in the last 3 years.
  • Receipt of blood products or immunoglobulin, within three months of study
  • Known or suspected coagulation disorder that in the opinion of the
  • investigator would contraindicate against receiving an intramuscular injection
  • or undergo frequent blood sampling.
  • Known anemia, measured as Hb < ( 8,5 mmol/l for men and 7,5 mmol/l for woman;
  • NHG standard Anemia)
  • Known to be positive for human immunodeficiency virus (HIV), and/or hepatitis
  • C virus (HCV) and/or hepatitis B virus (HBV).
  • Known or suspected immunodeficiency or use of immunosuppressive therapy that
  • according to the investigator, in consultation with a medical expert,
  • contraindicates a Prevnar-13 vaccination.
  • Exclusion criteria COVID-19 vaccination study
  • Treatment with COVID-19 monoclonal antibodies less that 3 months before
  • COVID-19 vaccination.
  • Known pregnancy at the moment of COVID-19 vaccination.

研究者

发起方
RIVM

相似试验